TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)
A phase 2 trial of TGRX-326 in non-small-cell lung cancer and small-cell lung cancer, run by Shenzhen TargetRx Co., Ltd., active and no longer recruiting.
Overview
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT05955391 by Shenzhen TargetRx Co., Ltd., with 164 participants enrolled, started 2023-01-18 and due to reach its primary completion in 2024-12-29. Interventions recorded: TGRX-326. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Setting
A Multi-centered, Open-label, Single-arm Phase II Study to Evaluate the Safety and Efficacy of TGRX-326 Monotherapy in Patients of Advanced ALK-positiveNon-Small Cell Lung Cancer Who Failed 2nd-Generation ALK Inhibitor Therapies
Phase
Phase 2
Sponsor
Shenzhen TargetRx Co., Ltd.
Registry
Enrolled
164